GREAT SCIENCE. GREAT MEDICINE.
CREATING BREAKTHROUGH TREATMENTS.
HGS is working to create and develop novel therapies that can extend and improve the quality of life. That is our passion.
Three Products in Late-Stage Development
We have three promising products in late-stage development – one already commercialized and two moving toward commercialization. BENLYSTA™ (belimumab) has successfully met its primary endpoint in two pivotal Phase 3 trials in systemic lupus, and we expect the submission of marketing applications in the United States, Europe and other regions in the first half of 2010. ZALBIN™ (albinterferon alfa-2b) has successfully completed Phase 3 development in chronic hepatitis C, and we expect the submission of global marketing applications in fourth quarter 2009. We are developing both of these products in collaboration with world leaders in the pharmaceutical industry.
In July 2009, we secured a new purchase order for 45,000 doses of raxibacumab to be delivered to the U.S. Strategic National Stockpile over a three-year period. In May, we submitted a Biologics License Application to the FDA for raxibacumab for the treatment of inhalation anthrax. The FDA has notified us that our BLA has been filed and will receive priority review.
High-Potential Pipeline
Right behind these late-stage products is an emerging, high-potential mid-stage pipeline, led by our TRAIL receptor antibody HGS-ETR1 for cancer. We also have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.
We are committed to improving the lives of patients – and to achieving commercial success and sustainable growth well into the future.